<?xml version='1.0' encoding='utf-8'?>
<document id="20163283"><sentence text="Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis." /><sentence text="Major adverse cardiovascular events including stent thrombosis associated with residual platelet reactivity on antiplatelet treatment in high risk vascular patients is a hot issue that needs a strong effort to be solved" /><sentence text=" Dual antiplatelet therapy with clopidogrel and aspirin prevents ischemic events and improves outcomes following acute coronary syndromes and percutaneous coronary intervention"><entity charOffset="32-43" id="DDI-PubMed.20163283.s3.e0" text="clopidogrel" /><entity charOffset="48-55" id="DDI-PubMed.20163283.s3.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.20163283.s3.e0" e2="DDI-PubMed.20163283.s3.e0" /><pair ddi="false" e1="DDI-PubMed.20163283.s3.e0" e2="DDI-PubMed.20163283.s3.e1" /></sentence><sentence text=" However, adverse cardiovascular events occur in these patients, and several studies have shown that patients who suffer cardiovascular complications have high post-treatment platelet reactivity despite antiplatelet treatment" /><sentence text=" Clopidogrel requires conversion to active metabolite by CYP isoenzymes"><entity charOffset="1-12" id="DDI-PubMed.20163283.s5.e0" text="Clopidogrel" /></sentence><sentence text=" Recently, CYP2C19*2 polymorphism (G681A nucleotide substitution) has been shown to be associated with decreased metabolisation of clopidogrel, poor antiaggregant effect and increased adverse cardiovascular events"><entity charOffset="131-142" id="DDI-PubMed.20163283.s6.e0" text="clopidogrel" /></sentence><sentence text="" /><sentence text="This review summarises the principal studies contributing to establish the relationship between CYP2C19*2 polymorphism and adverse outcomes in high risk patients on clopidogrel treatment"><entity charOffset="165-176" id="DDI-PubMed.20163283.s8.e0" text="clopidogrel" /></sentence><sentence text="" /><sentence text="Prospective studies are urgently needed to determine the clinical impact of a score that takes into account individual characteristics of patients - CYP2C19*2 genotypes, residual platelet reactivity, drug-drug interaction, as well as traditional and procedural risk factors - for the identification of the therapeutic strategy that provides the best benefit for the single subject" /><sentence text="" /></document>